Effect of propofol on vasoconstriction and calcium mobilization induced by Angiotensin II differs in aortas from normotensive and hypertensive rats.
1. Angiotensin (Ang) II is a potent vasopressor agent, involved in the short-term control of arterial blood pressure during anaesthesia. The aim of the present study was to test the hypothesis that propofol, a widely used intravenous anaesthetic agent, could alter the arterial response to AngII and to evaluate its effect in genetic hypertension. 2. We studied the effect of increasing concentrations of propofol (5.6 x 10-7 to 5.6 x 10-4 mol/L) on aortic ring maximal isometric tension elicited by AngII and on AngII-induced Ca2+ mobilization in aortic smooth muscle cells from Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). 3. Maximal tension developed by aortic rings from WKY rats was greater than that developed by rings from SHR. In both WKY rats and SHR, propofol at concentrations from 5.6 x 10-6 mol/L decreased maximal tension induced by AngII in a concentration-dependent manner. The magnitude of inhibition was higher in SHR than in WKY rats, whereas pD2 values were not different. In addition, Ca2+ mobilization induced by AngII was inhibited by propofol in a concentration-dependent manner, with the same magnitude and pD2 values. 4. These results suggest that the arterial response to AngII may be altered during propofol anaesthesia, particularly in hypertension.
Department of Medical Research, CNRS UMR 8078, Marie Lannelongue Hospital, University of Paris XI, Le Plessis-Robinson, France. elsamain@chu-besancon.fr
Emmanuel
E
Samain
Sébastien
S
Pili-Floury
Hélène
H
Bouillier
Adeline
A
Clichet
Michel
M
Safar
Georges
G
Dagher
Jean
J
Marty
Jean-François
JF
Renaud
D000804:Angiotensin II / Q000494:pharmacology / Q000502:physiology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002118:Calcium / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006973:Hypertension / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000378:metabolism / Q000502:physiology; D015742:Propofol / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D006993:Hypnotics and Sedatives; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D002118:Calcium; D015742:Propofol